The Pharma Data

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies to eliminate mesothelioma and other diseases, was part of a…

Read MoreRS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries

Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries Takeda today announces five new partnerships for its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in…

Read MoreTakeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity Ahead of discussions at the United Nations General Assembly (UNGA78), IFPMA, the association representing the research-based pharmaceutical industry, warned that…

Read MoreAhead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone…

Read MoreStudy Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance und Technik vereint, um beispiellose Effizienz und Exzellenz während des…

Read MoreIRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older Merck known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved…

Read MoreEuropean Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced…

Read MoreRoche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will celebrate a…

Read MoreBristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research